CN Patent

CN108276410B — 一种间变性淋巴瘤激酶抑制剂及其制备方法和用途

Assigned to Capital Pharmaceutical Holdings (beijing) Co Ltd · Expires 2021-12-10 · 4y expired

What this patent protects

本发明涉及式(I)化合物及其药物组合物和制备方法，其可用作ALK抑制剂来治疗由ALK介导的疾病。本发明还涉及式(I)化合物及其药物组合物在制备治疗由ALK介导的疾病的药物中的应用。

USPTO Abstract

本发明涉及式(I)化合物及其药物组合物和制备方法，其可用作ALK抑制剂来治疗由ALK介导的疾病。本发明还涉及式(I)化合物及其药物组合物在制备治疗由ALK介导的疾病的药物中的应用。

Drugs covered by this patent

Patent Metadata

Patent number
CN108276410B
Jurisdiction
CN
Classification
—
Expires
2021-12-10
Drug substance claim
No
Drug product claim
No
Assignee
Capital Pharmaceutical Holdings (beijing) Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.